New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
13:30 EDTDYAX, BCRXBioCryst data has favorable read through for Dyax, says Jefferies
After Biocryst (BCRX) reported positive data from a trial evaluating BCX4161 in hereditary angioedema, Jefferies said the study results point to higher odds for the success of Dyax's (DYAX) DX-2930, which has a similar pathway and is being developed as a prophylactic treatment for HAE. The firm maintains its Buy rating and $13.00 price target on Dyax.
News For DYAX;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2015
11:22 EDTDYAXOptions with decreasing implied volatility
Subscribe for More Information
11:07 EDTDYAXOptions with decreasing implied volatility
Subscribe for More Information
06:08 EDTDYAXDyax 7.4M share Secondary priced at $27.00
Subscribe for More Information
April 7, 2015
11:09 EDTDYAXOptions with decreasing implied volatility
Subscribe for More Information
April 6, 2015
19:27 EDTDYAXOn The Fly: After Hours Movers
Subscribe for More Information
17:29 EDTDYAXDyax sees Q1 KALBITOR net sales $15.6M-$16M
Q1 revenue consensus consensus $21.19M. On Monday, April 6, Dyax filed with the SEC a preliminary prospectus supplement relating to the sale of Dyax’s common stock in a proposed underwritten public offering. In connection with the offering, Dyax disclosed that KALBITOR gross sales for the quarter ended March 31, were approximately $17.6M; subject to final adjustments for gross to net sales data, net sales are estimated to be in a range of $15.6M-$16M. In addition, cash, cash equivalents and short-term investments totaled approximately $181.9M at March 31, 2015.
16:03 EDTDYAXDyax files to sell 7M shares of common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use